The role of external beam radiotherapy in the management of differentiated thyroid cancer

Well differentiated thyroid cancers (DTC), usually having an indolent course, are generally treated by surgery, i.e., total or near total thyroidectomy, followed by radioiodine and TSH suppressive therapy with thyroid hormone. The beneficial effect of external beam radiotherapy (EBRT) in the treatme...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 54; no. 6; pp. 345 - 349
Main Authors Mazzarotto, R., Cesaro, M.G., Lora, O., Rubello, D., Casara, D., Sotti, G.
Format Journal Article Conference Proceeding
LanguageEnglish
Published Paris Elsevier SAS 01.07.2000
Elsevier
Subjects
Biological and medical sciences
Bone Neoplasms - secondary
Brain Neoplasms - secondary
differentiated thyroid cancer
external beam radiotherapy
Humans
Medical sciences
Radiation therapy and radiosensitizing agent
radioiodine
Thyroid Neoplasms - radiotherapy
Treatment with physical agents
Treatment. General aspects
Tumors
external beam radiotherapy
differentiated thyroid cancer
radioiodine
Endocrinopathy
Human
Relapse
Thyroid diseases
Iodine Isotopes
Thyroid gland
Radioisotope
Malignant tumor
Radiotherapy
Resistance
Surgery
Risk factor
Advanced stage
Combined treatment
Online AccessGet full text

Cover

More Information
Summary:Well differentiated thyroid cancers (DTC), usually having an indolent course, are generally treated by surgery, i.e., total or near total thyroidectomy, followed by radioiodine and TSH suppressive therapy with thyroid hormone. The beneficial effect of external beam radiotherapy (EBRT) in the treatment of selected metastatic sites (i.e., brain and bone) or for palliation in cases of locally advanced inoperable disease is widely accepted. In contrast, its efficacy in improving postoperative locoregional disease control is still controversial. A better definition of subgroups of patients at high risk of local failure is mandatory. At present, patients older than 40–45 years affected by papillary cancers with macro- or microscopic postoperative residual disease and with extensive extrathyroid invasion appear to benefit from EBRT performed in addition to surgery and radioiodine. The role of EBRT in patients with radioiodine non-responsive progressive disease will also be discussed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0753-3322
1950-6007
DOI:10.1016/S0753-3322(00)80061-X